公开(公告)号：US08835456B1

公开(公告)日：2014-09-16

申请号：US13423935

申请日：2012-03-19

申请人： Jason Allan Wiles ,  Venkat Gadhachanada ,  Avinash Phadke ,  Milind Deshpande ,  Dawei Chen

发明人： Jason Allan Wiles ,  Venkat Gadhachanada ,  Avinash Phadke ,  Milind Deshpande ,  Dawei Chen

IPC分类号： A61K31/44 ,  C07D451/02

CPC分类号： C07D471/08 ,  A61K45/06

摘要： The invention provides compounds of Formula I and the pharmaceutically salts thereof. These compounds may be generally described as bridged-bicyclo indole-containing compounds. The variables shown in Formula I are defined herein. Certain compounds of Formula I are useful as antiviral agents. Compounds as disclosed herein are potent and/or selective inhibitors of viral replication, particularly Hepatitis C virus replication. The invention also provides pharmaceutical compositions containing one or more compounds of Formula I and at least one pharmaceutically acceptable carrier. Such pharmaceutical compositions may contain a compound of Formula I as the only active agent or may contain a combination of a compound of Formula I and one or more other pharmaceutically active agents. The invention also provides methods for treating viral infections, including Hepatitis C infections, in patients.

摘要翻译： 本发明提供式I化合物及其药学上可接受的盐。 这些化合物通常可以被描述为含桥连双环吲哚的化合物。 式I中所示的变量在本文中定义。 某些式I化合物可用作抗病毒剂。 本文公开的化合物是病毒复制的有效和/或选择性抑制剂，特别是丙型肝炎病毒复制。 本发明还提供含有一种或多种式I化合物和至少一种药学上可接受的载体的药物组合物。 这样的药物组合物可以含有式I化合物作为唯一的活性剂，或者可以含有式I化合物与一种或多种其它药物活性剂的组合。 本发明还提供了用于治疗患者中的病毒感染（包括丙型肝炎感染）的方法。

公开(公告)号：US08697641B2

公开(公告)日：2014-04-15

申请号：US12635049

申请日：2009-12-10

申请人： Avinash Phadke ,  Xiangzhu Wang ,  Godwin Pais ,  Akihiro Hashimoto ,  Venkat Gadhachanda ,  Dawei Chen ,  Atul Agarwal ,  Suoming Zhang ,  Cuixian Liu ,  Shouming Li ,  Milind Deshpande

发明人： Avinash Phadke ,  Xiangzhu Wang ,  Godwin Pais ,  Akihiro Hashimoto ,  Venkat Gadhachanda ,  Dawei Chen ,  Atul Agarwal ,  Suoming Zhang ,  Cuixian Liu ,  Shouming Li ,  Milind Deshpande

IPC分类号： A01N37/18

摘要： The invention provides 4-amino-4-oxobutanoyl peptides and cyclic analogues thereof of Formula I and the pharmaceutically salts thereof. The variables are defined herein. Certain compounds of Formula I are useful as antiviral agents. 4-amino-4-oxobutanoyl peptide cyclic analogues as disclosed herein are potent and/or selective inhibitors of viral replication, particularly Hepatitis C virus replication. The invention also provides pharmaceutical compositions containing one or more 4-amino-4-oxobutanoyl peptide cyclic analogues and one or more pharmaceutically acceptable carriers. Such pharmaceutical compositions may contain a 4-amino-4-oxobutanoyl peptide cyclic analogue as the only active agent or may contain a combination of a 4-amino-4-oxobutanoyl peptide cyclic analogue and one or more other pharmaceutically active agents. The invention also provides methods for treating viral infections, including Hepatitis C infections, in patients.

公开(公告)号：US20130171491A1

公开(公告)日：2013-07-04

申请号：US13340741

申请日：2011-12-30

申请人： Jinzhu Wei ,  Stephen Stone ,  Dawei Chen

发明人： Jinzhu Wei ,  Stephen Stone ,  Dawei Chen

IPC分类号： H01M10/50 ,  F28F99/00

CPC分类号： H01M10/486 ,  F28F3/12 ,  F28F2275/025 ,  H01M2/1077 ,  H01M10/6555 ,  H01M10/6557

摘要： An apparatus for transferring thermal energy to or from a battery cell is disclosed, which includes a thermally conductive plate enclosing a conduit in communication with an inlet for receiving a heat transfer fluid stream and being configured to cause the fluid to flow through the plate to an outlet. The plate has a surface for receiving thermal energy generated by operation of the battery cell and is operable to couple thermal energy to the fluid. In one aspect the plate includes first and second opposing walls and the conduit includes a first conduit portion formed in the first wall and a second corresponding conduit portion formed in the second wall defining the conduit. In another aspect the conduit includes an aperture in a central wall and first and second cover walls on either side of the central wall. The cover walls enclose aperture and provide a seal.

摘要翻译： 公开了一种用于将热能传送到电池单元或从电池单元传送热量的装置，其包括导热板，该导热板封闭与用于接收传热流体流的入口连通的导管，并且被配置为使流体流过该板至 出口。 板具有用于接收由电池单元的操作产生的热能的表面，并且可操作以将热能耦合到流体。 在一个方面，板包括第一和第二相对的壁，并且导管包括形成在第一壁中的第一导管部分和形成在限定导管的第二壁中的第二对应导管部分。 在另一方面，导管包括位于中心壁上的孔，中心壁两侧的第一和第二盖壁。 盖壁包围孔并提供密封。

公开(公告)号：US20100152103A1

公开(公告)日：2010-06-17

申请号：US12635049

申请日：2009-12-10

申请人： Avinash Phadke ,  Xiangzhu Wang ,  Godwin Pais ,  Akihiro Hashimoto ,  Venkat Gadhachanda ,  Dawei Chen ,  Atul Agarwal ,  Suoming Zhang ,  Cuixian Liu ,  Shouming Li ,  Milind Deshpande

发明人： Avinash Phadke ,  Xiangzhu Wang ,  Godwin Pais ,  Akihiro Hashimoto ,  Venkat Gadhachanda ,  Dawei Chen ,  Atul Agarwal ,  Suoming Zhang ,  Cuixian Liu ,  Shouming Li ,  Milind Deshpande

IPC分类号： A61K38/12 ,  C07K5/12 ,  A61P31/12

CPC分类号： C07K5/12 ,  A61K38/00 ,  C07K5/06165

摘要： The invention provides 4-amino-4-oxobutanoyl peptides and cyclic analogues thereof of Formula I and the pharmaceutically salts thereof.The variables are defined herein. Certain compounds of Formula I are useful as antiviral agents. 4-amino-4-oxobutanoyl peptide cyclic analogues as disclosed herein are potent and/or selective inhibitors of viral replication, particularly Hepatitis C virus replication. The invention also provides pharmaceutical compositions containing one or more 4-amino-4-oxobutanoyl peptide cyclic analogues and one or more pharmaceutically acceptable carriers. Such pharmaceutical compositions may contain a 4-amino-4-oxobutanoyl peptide cyclic analogue as the only active agent or may contain a combination of a 4-amino-4-oxobutanoyl peptide cyclic analogue and one or more other pharmaceutically active agents. The invention also provides methods for treating viral infections, including Hepatitis C infections, in patients.

摘要翻译： 本发明提供了式I的4-氨基-4-氧代丁酰基肽及其环状类似物及其药学上可接受的盐。 变量在此定义。 某些式I化合物可用作抗病毒剂。 本文公开的4-氨基-4-氧代丁酰基肽环类似物是病毒复制，特别是丙型肝炎病毒复制的有效和/或选择性抑制剂。 本发明还提供含有一种或多种4-氨基-4-氧代丁酰基肽环状类似物和一种或多种药学上可接受的载体的药物组合物。 这样的药物组合物可以含有4-氨基-4-氧代丁酰基肽环类似物作为唯一的活性剂，或者可以含有4-氨基-4-氧代丁酰基肽环类似物和一种或多种其它药物活性剂的组合。 本发明还提供了用于治疗患者中的病毒感染（包括丙型肝炎感染）的方法。

公开(公告)号：US07365068B2

公开(公告)日：2008-04-29

申请号：US11131013

申请日：2005-05-17

申请人： Avinash Phadke ,  Dawei Chen ,  Milind Deshpande ,  Andrew Thurkauf ,  Xiangzhu Wang ,  Yiping Shen ,  Cuixian Liu ,  Jesse Quinn ,  Junko Ohkanda ,  Shouming Li

发明人： Avinash Phadke ,  Dawei Chen ,  Milind Deshpande ,  Andrew Thurkauf ,  Xiangzhu Wang ,  Yiping Shen ,  Cuixian Liu ,  Jesse Quinn ,  Junko Ohkanda ,  Shouming Li

IPC分类号： A61K31/496 ,  A61K31/444 ,  A61K31/5377 ,  C07D211/78 ,  C07D401/02 ,  C07D401/06 ,  C07D413/02 ,  C07D413/06

CPC分类号： C07D295/15 ,  C07C335/26 ,  C07D211/22 ,  C07D211/46 ,  C07D211/60 ,  C07D211/64 ,  C07D211/78 ,  C07D213/56 ,  C07D213/82 ,  C07D215/54 ,  C07D231/14 ,  C07D233/54 ,  C07D233/64 ,  C07D233/90 ,  C07D237/24 ,  C07D239/28 ,  C07D241/24 ,  C07D241/44 ,  C07D249/06 ,  C07D253/07 ,  C07D261/18 ,  C07D263/34 ,  C07D263/58 ,  C07D265/30 ,  C07D271/12 ,  C07D277/56 ,  C07D277/68 ,  C07D285/06 ,  C07D307/68 ,  C07D307/84 ,  C07D307/85 ,  C07D309/38 ,  C07D311/58 ,  C07D333/38 ,  C07D401/04 ,  C07D401/12 ,  C07D405/04 ,  C07D409/04 ,  C07D409/12 ,  C07D413/12 ,  C07D417/04 ,  C07D417/12 ,  C07D417/14 ,  C07D419/12 ,  C07D471/04 ,  C07D487/04 ,  C07D491/04 ,  C07D495/04 ,  C07D513/04

摘要： The invention provides compounds and pharmaceutically acceptable salts of Formula I wherein the variables A1, A2, R1, R2, V, W, X, Y, and Z are defined herein. Certain compounds of Formula I described herein which possess potent antiviral activity. The invention particularly provides compounds of Formula I that are potent and/or selective inhibitors of Hepatitis C virus replication. The invention also provides pharmaceutical compositions containing one or more compound of Formula I, or a salt, solvate, or acylated prodrug of such compounds, and one or more pharmaceutically acceptable carriers, excipients, or diluents. The invention further comprises methods of treating patients suffering from certain infectious diseases by administering to such patients an amount of a compound of Formula I effective to reduce signs or symptoms of the disease or disorder. These infectious diseases include viral infections, particularly HCV infections. The invention is particularly includes methods of treating human patients suffering from an infectious disease, but also encompasses methods of treating other animals, including livestock and domesticated companion animals, suffering from an infectious disease.Methods of treatment include administering a compound of Formula I as a single active agent or administering a compound of Formula I in combination with on or more other therapeutic agent.

摘要翻译： 本发明提供式I的化合物和药学上可接受的盐，其中变量A 1，A 2，R 1，R 2， / SUB>，V，W，X，Y和Z在本文中定义。 某些本文所述的具有强抗病毒活性的式I化合物。 本发明特别提供了作为丙型肝炎病毒复制的有效和/或选择性抑制剂的式I化合物。 本发明还提供含有一种或多种式I化合物或这些化合物的盐，溶剂化物或酰化前药以及一种或多种药学上可接受的载体，赋形剂或稀释剂的药物组合物。 本发明还包括通过向这些患者施用一定量的有效减少疾病或病症的体征或症状的式I化合物来治疗患有某些感染性疾病的患者的方法。 这些传染病包括病毒感染，特别是HCV感染。 本发明特别包括治疗患有感染性疾病的人类患者的方法，还包括治疗其它动物（包括患有传染病的家畜和驯养的伴侣动物）的方法。 治疗方法包括给予式I化合物作为单一活性剂或将一种式I化合物与一种或多种其它治疗剂组合施用。

公开(公告)号：US20070085692A1

公开(公告)日：2007-04-19

申请号：US11550199

申请日：2006-10-17

申请人： Jeffrey Grant ,  J. Michael Weaver ,  Dawei Chen

发明人： Jeffrey Grant ,  J. Michael Weaver ,  Dawei Chen

IPC分类号： G08B17/10

CPC分类号： G08B21/14

摘要： A carbon monoxide detector is coupled to a gas-powered generator. The carbon monoxide detector is configured to provide notification when a predetermined concentration of carbon monoxide is reached and may also be utilized to disable the generator.

摘要翻译： 一氧化碳检测器耦合到气体发电机。 一氧化碳检测器被配置为当达到预定浓度的一氧化碳时提供通知，并且也可以用于禁用发生器。

公开(公告)号：US20070004711A1

公开(公告)日：2007-01-04

申请号：US11431155

申请日：2006-05-09

申请人： Suoming Zhang ,  Avinash Phadke ,  Cuixian Liu ,  Xiangzhu Wang ,  Jesse Quinn ,  Dawei Chen ,  Venkat Gadhachanda ,  Shouming Li ,  Milind Deshpande

发明人： Suoming Zhang ,  Avinash Phadke ,  Cuixian Liu ,  Xiangzhu Wang ,  Jesse Quinn ,  Dawei Chen ,  Venkat Gadhachanda ,  Shouming Li ,  Milind Deshpande

IPC分类号： A61K31/541 ,  A61K31/5377 ,  A61K31/496 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/426

CPC分类号： C07D487/04 ,  C07D277/38 ,  C07D277/42 ,  C07D417/04 ,  C07D417/06 ,  C07D417/12 ,  C07D417/14 ,  C07D513/04

摘要： The present invention provides compounds, salts and hydrates of Formula I, wherein the variables Ar1, R2, R3, R4, r, q, and t are defined herein. Certain compounds of Formula I described herein possess potent antiviral activity. The invention also provides compounds of Formula I that are potent and/or selective inhibitors of Hepatitis C virus replication. Certain compounds described herein inhibit assembly of the HCV replication complex. The invention also provides pharmaceutical compositions containing one or more compounds of Formula I, or a salt, solvate, or acylated prodrug of such compounds, and one or more pharmaceutically acceptable carriers, excipients, or diluents. The invention further comprises methods of treating patients suffering from certain infectious diseases by administering to such patients an amount of a compound of Formula I effective to reduce signs or symptoms of the disease. These infectious diseases include viral infections, particularly HCV infections. The invention is particularly includes methods of treating human patients suffering from an infectious disease, but also encompasses methods of treating other animals, including livestock and domesticated companion animals, suffering from an infectious disease. Methods of treatment include administering a compound of Formula I as a single active agent or administering a compound of Formula I in combination with on or more other therapeutic agent.

摘要翻译： 本发明提供式I的化合物，盐和水合物，其中变量Ar 1，R 2，R 3，R 3， 4，r，q和t在本文中定义。 某些本文所述的式I化合物具有有效的抗病毒活性。 本发明还提供了作为丙型肝炎病毒复制的有效和/或选择性抑制剂的式I化合物。 本文所述的某些化合物抑制HCV复制复合物的组装。 本发明还提供含有一种或多种式I化合物或这些化合物的盐，溶剂化物或酰化前药以及一种或多种药学上可接受的载体，赋形剂或稀释剂的药物组合物。 本发明还包括通过向这些患者施用一定量的有效降低疾病体征或症状的式I化合物来治疗患有某些感染性疾病的患者的方法。 这些传染病包括病毒感染，特别是HCV感染。 本发明特别包括治疗患有感染性疾病的人类患者的方法，还包括治疗其它动物（包括患有传染病的家畜和驯养的伴侣动物）的方法。 治疗方法包括给予式I化合物作为单一活性剂或将一种式I化合物与一种或多种其它治疗剂组合施用。

公开(公告)号：US06443130B1

公开(公告)日：2002-09-03

申请号：US09749363

申请日：2000-12-27

申请人： Chris Turner ,  Robert D. Kern ,  Gerald C. Ruehlow ,  Jeff Vranak ,  Dawei Chen

发明人： Chris Turner ,  Robert D. Kern ,  Gerald C. Ruehlow ,  Jeff Vranak ,  Dawei Chen

IPC分类号： F02M4100

CPC分类号： F02M21/0239 ,  F02M21/0212 ,  F02M21/0215 ,  F02M21/0233 ,  Y02T10/32

摘要： A fuel regulator is provided for regulating the supply of fuel to a multi-cylinder engine. The regulator includes a regulator body defining a holding chamber connectable to a fuel source; a first supply chamber connectable to a first cylinder of the multi-cylinder engine; and a second supply chamber connectable to a second cylinder of the multi-cylinder engine. Orifices are provided between the supply chambers and the holding chamber. A first regulating structure is movable between a closed position wherein the orifice between the holding chamber and the first supply chamber is closed and an open position wherein the orifice between the holding chamber and the supply chamber is open in response to the fuel demanded by the first cylinder of the multi-cylinder engine. A second regulating structure is also movable between a closed position wherein the orifice between the holding chamber and the second supply chamber is closed and an open position wherein the orifice between the holding chamber and the second supply chamber is opened in response to the fuel demanded by the second cylinder of the engine.

摘要翻译： 提供了一种用于调节向多气缸发动机供应燃料的燃料调节器。 调节器包括限定可连接到燃料源的保持室的调节器主体; 可连接到所述多气缸发动机的第一气缸的第一供应室; 以及可连接到多缸发动机的第二气缸的第二供应室。 在供给室和保持室之间设置有孔。 第一调节结构可在关闭位置和关闭位置之间移动，在关闭位置，其中保持室和第一供应室之间的孔关闭，并且打开位置，其中保持室和供应室之间的孔响应于第一 多缸发动机气缸。 第二调节结构还可以在闭合位置之间移动，在关闭位置，其中保持室和第二供应室之间的孔关闭，并且打开位置，其中保持室和第二供应室之间的孔响应于由 发动机的第二缸。

公开(公告)号：US20240024346A1

公开(公告)日：2024-01-25

申请号：US18021709

申请日：2021-11-25

申请人： RISEN (SUZHOU) PHARMA TECH CO., LTD. ,  Jiasheng LU ,  Gang CHEN ,  Qiguo ZHANG ,  Xianqi KONG ,  Dawei CHEN ,  Chuanhao HUANG ,  Xingwu ZHU ,  Yuhua ZHANG

发明人： Jiasheng LU ,  Gang CHEN ,  Qiguo ZHANG ,  Xianqi KONG ,  Dawei CHEN ,  Chuanhao HUANG ,  Xingwu ZHU ,  Yuhua ZHANG

IPC分类号： A61K31/7076 ,  C07H19/20 ,  A61K45/06

CPC分类号： A61K31/7076 ,  A61K45/06 ,  C07H19/20

摘要： CD73 (also known as ecto-5′-nucleotidase) inhibitor compounds are provided, as well as compositions and uses thereof for treating or preventing CD73-associated or related diseases, disorders and conditions, including cancer- and immune-related disorders. CD73 inhibitor compounds include compounds having the structure set forth in Formula I′ and pharmaceutically acceptable esters or salts thereof.

公开(公告)号：US20140113890A1

公开(公告)日：2014-04-24

申请号：US14139196

申请日：2013-12-23

申请人： Avinash Phadke ,  Dawei Chen ,  Venkat Gadhachanda ,  Akihiro Hashimoto ,  Godwin Pais ,  Xiangzhu Wang ,  Atul Agarwal ,  Ha Young Kim ,  Shuoming Li ,  Cuixian Liu ,  Suoming Zhang ,  Milind Deshpande

发明人： Avinash Phadke ,  Dawei Chen ,  Venkat Gadhachanda ,  Akihiro Hashimoto ,  Godwin Pais ,  Xiangzhu Wang ,  Atul Agarwal ,  Ha Young Kim ,  Shuoming Li ,  Cuixian Liu ,  Suoming Zhang ,  Milind Deshpande

IPC分类号： C07D207/16 ,  C07D401/14 ,  C07D413/14 ,  C07D417/12 ,  C07D409/14 ,  C07D491/113 ,  C07D487/18 ,  C07D417/14 ,  C07D401/12 ,  C07D403/12

CPC分类号： C07D207/16 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D403/14 ,  C07D409/14 ,  C07D413/14 ,  C07D417/12 ,  C07D417/14 ,  C07D471/08 ,  C07D487/08 ,  C07D487/18 ,  C07D491/113

摘要： The invention provides 4-amino-4-oxobutanoyl peptides of Formula I and the pharmaceutically salts and hydrates thereof. The variables R, R1, R6-R8, R16, R18, R19, M, n, T, Y, and Z are defined herein. Certain compounds of Formula I are useful as antiviral agents. The 4-amino-4-oxobutanoyl peptides disclosed herein are potent and/or selective inhibitors of viral replication, particularly Hepatitis C virus replication. The invention also provides pharmaceutical compositions containing one or more 4-amino-4-oxobutanoyl peptides and one or more pharmaceutically acceptable carriers. Such pharmaceutical compositions may contain a 4-amino-4-oxobutanoyl peptides as the only active agent or may contain a combination of a 4-amino-4-oxobutanoyl peptides and one or more other pharmaceutically active agents. The invention also provides methods for treating viral infections, including Hepatitis C infections.

摘要翻译： 本发明提供式I的4-氨基-4-氧代丁酰基肽及其药学上可接受的盐和水合物。 变量R，R1，R6-R8，R16，R18，R19，M，n，T，Y和Z在本文中定义。 某些式I化合物可用作抗病毒剂。 本文公开的4-氨基-4-氧代丁酰基肽是有效和/或选择性的病毒复制抑制剂，特别是丙型肝炎病毒复制。 本发明还提供含有一种或多种4-氨基-4-氧代丁酰基肽和一种或多种药学上可接受的载体的药物组合物。 这样的药物组合物可以含有4-氨基-4-氧代丁酰基肽作为唯一的活性剂，或者可以含有4-氨基-4-氧代丁酰基肽和一种或多种其它药物活性剂的组合。 本发明还提供了治疗病毒感染的方法，包括丙型肝炎感染。